Predictors of detectable IgG in infants at delivery also included third-trimester infection, mild\/moderate and severe\/critical disease<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Oct. 19, 2022 (HealthDay News) — For women with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in pregnancy, vaccination after recovery is associated with increased odds of detectable immunoglobulin (Ig)G in infants, according to a study published online Sept. 9 in The<\/em> Journal of Infectious Diseases<\/em>.<\/p>\n Mary C. Cambou, M.D., from the University of California, Los Angeles, and colleagues conducted a study in a longitudinal cohort of pregnant women with SARS-CoV-2 infection. Maternal\/infant sera were obtained at enrollment (from 256 pregnant women and 135 infants), delivery\/birth (148 maternal and 122 neonatal specimens), and six months (45 maternal and 48 infant specimens).<\/p>\n The researchers found that 68 percent of women produced all anti-SARS-CoV-2 isotypes at delivery (IgG, IgM, and IgA); 96 percent had one or more isotype. Higher maternal IgG at labor and delivery was seen in association with symptomatic disease and vaccination before delivery. There was a decrease in detectable IgG in infants, from 78 percent at birth to 52 percent at six months. Significant predictors of detectable IgG in infants at delivery included third-trimester infection, mild\/moderate disease, severe\/critical disease, and maternal vaccination before delivery (odds ratios, 4.0, 4.8, 6.3, and 18.8, respectively). At six months postpartum, no factors were significant.<\/p>\n “Vaccination following infection and prior to delivery was the strongest predictor of infant antibodies at birth. Notably, infant levels dropped significantly by 6 months, emphasizing the importance of starting the COVID vaccine series as early as 6 months,” Cambou said in a statement.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n